CA2571424A1 - Derives de bisaryluree utiles pour inhiber chk1 - Google Patents

Derives de bisaryluree utiles pour inhiber chk1 Download PDF

Info

Publication number
CA2571424A1
CA2571424A1 CA002571424A CA2571424A CA2571424A1 CA 2571424 A1 CA2571424 A1 CA 2571424A1 CA 002571424 A CA002571424 A CA 002571424A CA 2571424 A CA2571424 A CA 2571424A CA 2571424 A1 CA2571424 A1 CA 2571424A1
Authority
CA
Canada
Prior art keywords
cancer
group
methyl
compound
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002571424A
Other languages
English (en)
Inventor
Laurence Edward Burgess
Adam Wade Cook
Kimba L. Fischer
John Joseph Gaudino
Stephen T. Schlachter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corporation
Laurence Edward Burgess
Adam Wade Cook
Kimba L. Fischer
John Joseph Gaudino
Stephen T. Schlachter
Array Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corporation, Laurence Edward Burgess, Adam Wade Cook, Kimba L. Fischer, John Joseph Gaudino, Stephen T. Schlachter, Array Biopharma filed Critical Icos Corporation
Publication of CA2571424A1 publication Critical patent/CA2571424A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
CA002571424A 2004-06-25 2005-06-24 Derives de bisaryluree utiles pour inhiber chk1 Abandoned CA2571424A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58308004P 2004-06-25 2004-06-25
US60/583,080 2004-06-25
PCT/US2005/022515 WO2006012308A1 (fr) 2004-06-25 2005-06-24 Dérivés de bisarylurée utiles pour inhiber chk1

Publications (1)

Publication Number Publication Date
CA2571424A1 true CA2571424A1 (fr) 2006-02-02

Family

ID=35307890

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002571424A Abandoned CA2571424A1 (fr) 2004-06-25 2005-06-24 Derives de bisaryluree utiles pour inhiber chk1

Country Status (9)

Country Link
EP (1) EP1765808A1 (fr)
JP (1) JP2008504283A (fr)
KR (1) KR20070028591A (fr)
CN (1) CN101006075A (fr)
AU (1) AU2005267185A1 (fr)
BR (1) BRPI0512593A (fr)
CA (1) CA2571424A1 (fr)
MX (1) MX2007000259A (fr)
WO (1) WO2006012308A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101115727A (zh) * 2004-08-19 2008-01-30 艾科斯有限公司 用于抑制chk1的化合物
SI1869020T1 (sl) 2005-03-29 2011-02-28 Icos Corp Derivati heteroaril uree, ki so uporabni za inhibicijo chk1
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
WO2023287839A2 (fr) * 2021-07-13 2023-01-19 Brown University Traitement du cancer du tractus urinaire guidé par le paysage mutationnel
CA3233080A1 (fr) * 2021-09-28 2023-04-06 Pioneer Hi-Bred International, Inc. Conditions de germination et de croissance de semis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01163723A (ja) * 1987-12-21 1989-06-28 Nippon Telegr & Teleph Corp <Ntt> 有機非線形光学材料
JPH09249628A (ja) * 1996-03-12 1997-09-22 Tanabe Seiyaku Co Ltd フェノール誘導体
ATE297383T1 (de) * 1997-12-22 2005-06-15 Bayer Pharmaceuticals Corp Hemmung der p38 kinase unter verwendung von symmetrischen und asymmetrischen diphenylharnstoffen
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2003022273A1 (fr) * 2001-09-13 2003-03-20 Boehringer Ingelheim Pharmaceuticals, Inc. Methodes de traitement de maladies mediees par la cytokine
US20030236287A1 (en) * 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors

Also Published As

Publication number Publication date
BRPI0512593A (pt) 2008-03-25
KR20070028591A (ko) 2007-03-12
EP1765808A1 (fr) 2007-03-28
CN101006075A (zh) 2007-07-25
WO2006012308A1 (fr) 2006-02-02
AU2005267185A1 (en) 2006-02-02
MX2007000259A (es) 2007-07-20
JP2008504283A (ja) 2008-02-14

Similar Documents

Publication Publication Date Title
US7560462B2 (en) Compounds useful for inhibiting CHK1
AU2002258451B2 (en) Aryl and Heteroaryl Urea CHK1 Inhibitors for Use as Radiosensitizers and Chemosensitizers
US20080318974A1 (en) Compounds Useful for Inhibiting Chk1
AU2006230337B2 (en) Heteroaryl urea derivatives useful for inhibiting Chk1
CA2463822A1 (fr) Heteroaryl amines utiles comme inhibiteurs de glycogene synthase kinase 3beta (inhibiteurs de gsk3)
CA2463821A1 (fr) Derives amides utilises en tant qu&#39;inhibiteurs de la glycogene synthase kinase 3-beta
AU2002258451A1 (en) Aryl and Heteroaryl Urea CHK1 Inhibitors for Use as Radiosensitizers and Chemosensitizers
CA2571424A1 (fr) Derives de bisaryluree utiles pour inhiber chk1

Legal Events

Date Code Title Description
FZDE Discontinued